Pembrolizumab Monotherapy in Patients With Primary Refractory Classical Hodgkin Lymphoma: Subgroup Analysis of the Phase 2 Keynote-087 Study

Hematological Oncology - United Kingdom
doi 10.1002/hon.2437_125